Efficacy and Safety of Chinese Herbal Formula Granules in Treating Chronic Kidney Disease Stage 3: A Multicenter, Randomized, Placebo-Controlled, Double-Blind Clinical Trial

Table 15

Change from baseline in safety outcomes over the 24-week follow-up period.

Variable	Treatment group	Control group	value time effect	value group comparison
White blood cell (×10^12/L)
Pretreatment	6.49 ± 2.16	6.49 ± 1.81	0.2003	0.9694
Week 24	6.53 ± 1.99	6.51 ± 1.86
Red blood cell (×10^12/L)
Pretreatment	4.40 ± 0.54	4.53 ± 0.62	0.0842	0.1398
Week 24	4.46 ± 0.56	4.69 ± 0.64
Platelet count (×10^12/L)
Pretreatment	178.23 ± 49.27	190.31 ± 51.67	0.2136	0.2415
Week 24	192.03 ± 53.51	197.12 ± 53.75
Albumin (g/L)
Pretreatment	42.92 ± 3.92	42.87 ± 6.03	0.2117	0.3561
Week 24	44.28 ± 3.01	43.16 ± 3.90
ALT (IU/L)
Pretreatment	26.60 ± 15.62	23.91 ± 12.27	0.8650	0.2324
Week 24	26.52 ± 15.46	26.03 ± 11.39
AST (IU/L)
Pretreatment	25.83 ± 13.00	23.33 ± 10.15	0.6925	0.5820
Week 24	26.14 ± 12.69	23.72 ± 8.72
Blood potassium (mmol/L)
Pretreatment	4.38 ± 0.62	4.34 ± 0.65	0.4012	0.8847
Week 24	4.58 ± 0.59	4.33 ± 0.53